Longeveron Granted U.S. Patent for Stem Cell Therapy Targeting Aging-Related Frailty
I'm PortAI, I can summarize articles.
Longeveron Inc. has been granted a U.S. patent for its mesenchymal stem cell therapy aimed at treating aging-related frailty. The patent, valid until 2038, covers the use of isolated allogeneic MSCs to alleviate symptoms like weakness and exhaustion in older patients. The company's lead therapy, laromestrocel, has shown promising results in two clinical trials focused on this condition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments